London-based Purespring raised €95M in a Series B funding round led by Sofinnova Partners to initiate a Phase I/II clinical trial for IgAN.

Oct 12, 2024•about 1 year ago

Amount Raised

€95 Million

LondonBiotechnology

Investors

Syncona LimitedBritish Patient CapitalGilde HealthcareForbionSofinnova Partners

Description

Purespring has secured £80M (approx €95M) in an oversubscribed Series B funding round. The funding will support its pipeline, including initiating a clinical trial for a chronic kidney disease.

Company Information

Company

Purespring Therapeutics

Location

London, England, United Kingdom

About

Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends